Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit

Tricia Ward interviews Gervasio Lamas TACT2, a trial of chelation therapy to lower CV risk presented at the 2024 ACC Scientific Sessions, and why its findings differed from those of TACT.theheart.org on Medscape

Source: Medscape Cardiology Headlines - April 16, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news